Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Ovid Therapeutics ( (OVID) ).
On December 18, 2025, Ovid Therapeutics reported Phase 1 results for OV350, the first known direct activator of the potassium-chloride cotransporter 2 (KCC2) to be dosed in humans, showing a favorable safety and tolerability profile with no treatment-related serious adverse events, predictable pharmacokinetics, and exploratory qEEG data consistent with central KCC2 modulation. The intravenous “tool” program achieved pharmacologically active exposure levels and provided key human safety and mechanistic data that underpin Ovid’s decision to halt further IV development of OV350 while accelerating its more potent, oral KCC2 activators, particularly OV4071, which is slated to enter Phase 1/1b testing in 2026 for psychosis associated with Parkinson’s disease and Lewy body dementia and potentially other neuropsychiatric conditions, bolstering the company’s positioning in first-in-class therapies targeting neural hyperexcitability.
The most recent analyst rating on (OVID) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Ovid Therapeutics stock, see the OVID Stock Forecast page.
Spark’s Take on OVID Stock
According to Spark, TipRanks’ AI Analyst, OVID is a Neutral.
Ovid Therapeutics’ stock score is primarily influenced by its financial performance challenges, including inconsistent revenue and ongoing losses. However, positive technical indicators and recent corporate events, such as securing significant funding and regaining Nasdaq compliance, provide some optimism. The valuation remains a concern due to negative earnings and lack of dividends.
To see Spark’s full report on OVID stock, click here.
More about Ovid Therapeutics
Ovid Therapeutics Inc., based in New York and listed on Nasdaq, is a biopharmaceutical company developing small-molecule medicines for brain disorders and symptoms driven by excess neural excitability. Its pipeline includes OV329, a next-generation GABA-aminotransferase inhibitor for treatment-resistant seizures and other indications, and a portfolio of KCC2 direct activators such as OV4071 and additional candidates aimed at restoring excitatory/inhibitory balance in the brain across multiple neurological and neuropsychiatric conditions.
Average Trading Volume: 2,869,337
Technical Sentiment Signal: Buy
Current Market Cap: $110.4M
For an in-depth examination of OVID stock, go to TipRanks’ Overview page.